Article Details

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in ...

Retrieved on: 2021-09-01 05:03:45

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in .... View article details on hiswai:

Excerpt

The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up